Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC
Starting Dose 20 units (0.6mg) Form Injectable vial (5mL, 3mg/mL, 15mg total) Dosing Protocol 20 units subcutaneous injection daily, Monday to Friday
No reader of this post should act or refrain from acting on the basis of any information included in, or accessible through, this post without seeking the appropriate medical advice on the particular facts and circumstances at issue from a licensed medical professional in the recipients state, country or other appropriate licensing jurisdiction.
Test at baseline before starting semaglutide
Subcutaneous injection in the lower back, approximately 1 to 2 inches lateral to the spine at the affected level, is the standard research approach
The compound shows activity at extremely low concentrations in laboratory settings, sometimes as little as 0.01 nanomolar
